Skip to main content
Ashington Innovation PLC logo

Ashington Innovation PLC — Investor Relations & Filings

Ticker · ASHI ISIN · GB00BNM4K334 LEI · 213800ZAKVIK5KORQ942 IL Financial and insurance activities
Open in API
Filings indexed 45 across all filing types
Latest filing 2023-11-08 Board/Management Inform…
Country GB United Kingdom
Listing IL ASHI

About Ashington Innovation PLC

https://www.ashingtoninnovation.com/

Ashington Innovation PLC is a special purpose acquisition company (SPAC), also known as a blank check company. It was formed to raise capital through public markets to fund the acquisition of an existing private company or business. The company's primary objective is to identify and merge with a target entity, focusing on opportunities within the technology sector. It has a particular emphasis on businesses in deep technology and financial services technology. As a SPAC, the company does not have its own commercial operations; its business model is contingent on completing a successful acquisition. The ultimate goal is to manage the acquired entity to generate an attractive rate of return for shareholders, primarily through capital appreciation.

Recent filings

Filing Released Lang Actions
Board changes
Board/Management Information Classification · 98% confidence The document is clearly identified as an RNS announcement (RNS Number : 8310S) from Ashington Innovation PLC, dated 08 November 2023. The core content is a 'Press Release' announcing 'Board changes'—specifically, the appointment of two non-executive directors and the resignation of one. This directly matches the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific subject matter (board changes) is more precise than the general 'RNS' or 'Regulatory Filings' category.
2023-11-08 English
Appointment of Non-Executive Director
Board/Management Information Classification · 98% confidence The document is identified by the 'RNS Number' and explicitly states it is a 'Press Release' from 'Ashington Innovation plc'. The content announces the 'Appointment of Non-Executive Director' and includes contact information for 'Tancredi Intelligent Communication' and disclosures related to the London Stock Exchange's regulatory framework ('Listing Rules Disclosures'). The presence of the RNS header, the nature of the announcement (director change), and the explicit mention of RNS as the information provider strongly indicate this is a general regulatory announcement. Since 'Board/Management Information' (MANG) is a specific category for director changes, and this is a formal announcement of that change, MANG is the most appropriate classification over the general 'RNS' fallback. The document length is moderate, but the content is a direct announcement, not a placeholder for a larger report.
2023-10-16 English
Update on Cell Therapy and Calon Discussions
Regulatory Filings Classification · 100% confidence The document is identified by the RNS Number and the header indicating it is a 'Press Release' distributed via RNS, which is approved by the FCA as a Primary Information Provider. The content discusses ongoing negotiations for potential acquisitions (M&A activity) and a change in the company's broker. Since the core subject is an update on strategic corporate actions (potential M&A and broker change) released through the official regulatory news service (RNS), and it doesn't fit neatly into specific financial report categories (like 10-K, ER, or IR), it falls under the general regulatory announcement category. Given the nature of the announcement (update on strategic corporate activity via RNS), the most appropriate classification is RNS, the general regulatory filing category, as it is not a specific report type like M&A Activity (TAR) which usually relates to the formal filing of a scheme document or offer details, but rather an update on the process.
2023-09-05 English
Heads of Terms Signed for the Acquisition of Calon
M&A Activity Classification · 100% confidence The document is identified by the RNS Number header and the closing statement indicating it is provided by RNS, the news service of the London Stock Exchange, which acts as a Primary Information Provider. The content details a significant corporate action: a non-binding Heads of Terms agreement for the acquisition of Calon Cardio-Technology Limited, contingent on a prior reverse takeover of Cell Therapy Limited. This announcement concerns a potential merger/acquisition activity (TAR) and is being disseminated via a regulatory news service. Since the core subject is the announcement of a proposed takeover/acquisition, the most specific code is TAR (M&A Activity). However, because the document is explicitly formatted and distributed through the RNS system, and it is a general announcement of corporate activity rather than a specific financial report or proxy material, it also strongly fits the Regulatory Filings (RNS) category, which often serves as the distribution channel identifier for such news. Given the content is a detailed press release about a proposed takeover, TAR is the most accurate content classification. If TAR were not available, RNS would be the fallback. Since TAR is available and the document is clearly about a takeover proposal, TAR is selected.
2023-08-24 English
Dual Listing on the Frankfurt Stock Exchange
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as an 'RNS Number' announcement from 'Ashington Innovation plc' dated August 21, 2023. The content announces a 'Dual Listing on the Frankfurt Stock Exchange' and mentions a previous announcement regarding a reverse takeover. The document structure, including the RNS header and the closing statement indicating it is provided by RNS, the news service of the London Stock Exchange, strongly suggests this is a general regulatory announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific corporate action like a dividend (DIV) or share repurchase (POS), the most appropriate general category for a routine regulatory news service update is 'Regulatory Filings' (RNS). The document length is short (3818 chars), which aligns with the 'MENU VS MEAL' rule suggesting it's an announcement rather than the full report.
2023-08-21 English
Heads of Terms Signed
M&A Activity Classification · 99% confidence The document is an official announcement released via RNS (Regulatory Information Service) of the London Stock Exchange, indicated by the RNS Number and the concluding boilerplate text. The content details a 'Proposed Reverse Takeover of Cell Therapy Limited' by Ashington Innovation PLC, which is a SPAC. A reverse takeover (RTO) is a significant corporate transaction, often involving the acquisition of a private company by a listed shell company, which frequently triggers mandatory suspension of listing and requires regulatory approval (FCA, Takeover Panel). This type of announcement, detailing a major corporate action like a takeover proposal, fits best under the 'M&A Activity' category (TAR). While it is a regulatory filing (RNS), TAR is more specific to the subject matter (Takeover/Merger). Since the document is a detailed press release announcing the Heads of Terms for the acquisition, it is classified as TAR rather than just a general RNS filing or an RPA (which usually just announces the publication of a report).
2023-08-17 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.